Korean J Gastroenterol.  2021 Jul;78(1):59-64. 10.4166/kjg.2021.059.

Prostate Cancer Presenting with Pruritus and Cholestasis

• Kim YH
• Park JM
• Kang CD
• Seo SO
• Lee K
• Song G

• KMID: 2518756
• DOI: http://doi.org/10.4166/kjg.2021.059

Abstract

Jaundice is a rare symptom of the paraneoplastic syndrome associated with prostate cancer. We report a case of metastatic prostate cancer that presented as jaundice. There was an absence of biliary obstruction and hepatic metastasis; therefore, the paraneoplastic syndrome was suggested as the etiology of cholestasis. Jaundice improved with the treatment of prostate cancer. In the literature, interleukin-6 has been suggested to be associated with paraneoplastic syndrome.

Keyword

Prostatic neoplasms; Cholestasis; Paraneoplastic syndromes; Interleukin-6

Figure

• 

  Fig. 1 Computed tomography showed (A) no findings of metastasis, hepatic infiltration, and no bile duct dilation or obstruction (B) heterogeneous enhancement of the prostate. (C) The whole body bone scan was suggestive of multiple bone metastases.

• 

  Fig. 2 (A) Prostate biopsy revealed adenocarcinoma (hematoxylin and eosin stain, ×100). (B) Liver biopsy showed cholestasis and nodular inflammation (hematoxylin and eosin stain, ×200).

• 

  Fig. 3 Clinical course of the patient. From the 14th day of hospitalization, leuprorelin was injected every 3 months, and bicalutamide was administered daily. Total bilirubin level gradually decreased.

Reference

1. Hinostroza-Yanahuaya J, Mon-Mon C, Ortega-Marcos O, Herrero-Berron JC, Ortiz-Libreros M, Vigil-Medina A. 2013; Stauffer syndrome and prostate carcinoma, two cases in chronic haemodialysis patients. Nefrologia. 33:749–750.

2. Sharma N, Darr U, Darr A, Sood G. 2019; Stauffer syndrome: a comprehensive review of the icteric variant of the syndrome. Cureus. 11:e6032. DOI: 10.7759/cureus.6032.

3. Reddy AN, Grosberg SJ, Wapnick S. 1977; Intermittent cholestatic jaundice and nonmetastatic prostatic carcinoma. Arch Intern Med. 137:1616–1618. DOI: 10.1001/archinte.1977.03630230088024. PMID: 921451.

4. Karakolios A, Kasapis C, Kallinikidis T, Kalpidis P, Grigoriadis N. 2003; Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol. 1:480–483. DOI: 10.1016/S1542-3565(03)00227-1.

5. Koruk M, Büyükberber M, Savaş C, Kadayifçi A. 2004; Paraneoplastic cholestasis associated with prostate carcinoma. Turk J Gastroenterol. 15:53–55.

6. Shah SH. 2006; Paraneoplastic liver dysfunction in prostate cancer. J Pain Symptom Manage. 32:511–513. DOI: 10.1016/j.jpainsymman.2006.03.015. PMID: 17157749.

7. Nguyen V, Gurney H, van der Poorten D. 2011; Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation. J Clin Oncol. 29:e21–e23. DOI: 10.1200/JCO.2010.30.6522. PMID: 20940196.

8. Kuramoto T, Senzaki H, Koike H, et al. 2013; Cholestatic jaundice as a paraneoplastic manifestation of prostate cancer. Case Rep Urol. 2013:303727. DOI: 10.1155/2013/303727. PMID: 24191227. PMCID: PMC3804369.

9. Okano A, Ohana M, Kusumi F. 2014; Idiopathic cholestatic jaundice may be a paraneoplastic manifestation of underlying malignancy: a case of prostate cancer. Clin J Gastroenterol. 7:278–282. DOI: 10.1007/s12328-014-0484-4. PMID: 26183750.

10. Kato D, Okwara C, Moreland C, Parker A. 2014; Hepatic dysfunction as a paraneoplastic manifestation of metastatic prostate adenocarcinoma. J Investig Med High Impact Case Rep. 2:2324709614539927. DOI: 10.1177/2324709614539927. PMID: 26425613. PMCID: PMC4528893.

11. Walter H, Backus N, Aragon G. 2015; Intrahepatic cholestasis in the setting of recurrent prostate cancer: a paraneoplastic syndrome. Am J Gastroenterol. 110:S394. DOI: 10.14309/00000434-201510001-00913.

12. Vieira AC, Alvarenga MJ, Santos JC, Silva AM. 2017; Paraneoplastic jaundice and prostate cancer. BMJ Case Rep. 2017:bcr2016218001. DOI: 10.1136/bcr-2016-218001. PMID: 28433972. PMCID: PMC5534789.

13. Bhangoo MS, Cheng B, Botta GP, Thorson P, Kosty MP. 2018; Reversible intrahepatic cholestasis in metastatic prostate cancer: an uncommon paraneoplastic syndrome. Mol Clin Oncol. 8:609–612. DOI: 10.3892/mco.2018.1564. PMID: 29541472. PMCID: PMC5838296.

14. Ravindranathan D, Hitron EE, Russler GA, Xue Y, Bilen MA. 2018; Metastatic prostate cancer manifesting as cholestatic jaundice: a case report and review of the literature. Case Rep Oncol Med. 2018:1809432. DOI: 10.1155/2018/1809432. PMID: 29780650. PMCID: PMC5892301.

15. Kang MK, Park JG, Lee HJ. 2018; Cholestatic jaundice as a paraneoplastic manifestation of prostate cancer aggravated by steroid therapy. Med Princ Pract. 27:197–200. DOI: 10.1159/000486717. PMID: 29320775. PMCID: PMC5968241.

16. Romašovs A, Puķītis A, Mokricka V, Frolova E. 2019; Stauffer's syndrome in patient with metastatic prostate cancer. Case Rep Urol. 2019:9745301. DOI: 10.1155/2019/9745301. PMID: 31179152. PMCID: PMC6501217.

17. Liu J, Agyapong G, Misra D, Taylor CD, Hirsh DA. 2019; A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancer. Clin Case Rep. 7:2068–2073. DOI: 10.1002/ccr3.2427. PMID: 31788253. PMCID: PMC6878062.

18. Gökçen P, Gökçen K, Çakmak E, Gökçe G. 2018; Paraneoplastic hyperbilirubinemia in metastatic prostate cancer and review of the current literature. Turk J Urol. 45:70–72. DOI: 10.5152/tud.2018.52059. PMID: 30668309. PMCID: PMC6342570.

19. Blay JY, Rossi JF, Wijdenes J, et al. 1997; Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer. 72:424–430. DOI: 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R.